alexa CXCR7: A Potential Target For Anti-angiogenesis Treatment
ISSN: 2161-0533

Orthopedic & Muscular System: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference and Exhibition on Orthopedics & Rheumatology
August 19-21, 2013 Embassy Suites Las Vegas, NV, USA

Cai Shaoxi
Accepted Abstracts: Orthop Muscul Syst
DOI: 10.4172/2161-0533.S1.014
Abstract
A ngiogenesis is an important pathogenic process implicated in rheumatoid arthritis (RA), and anti-angiogenesis treatment is potential strategy for RA therapy. Recent studies suggest that endothelial progenitor cells (EPC) are involved in synovial vascularization, and may contribute to the increased cardiovascular morbidity and mortality in RA. EPC is trigger of angiogenesis. During angiogenesis, EPC are mobilized from bone marrow, recruited to angiogenic site, incorporate and finally form neo-vessel. In those processes, stromal cell-derived factor-1 (SDF-1) is a main regulator. For a long time, SDF-1 was considered to act via its unique receptor CXCR4. CXCR7 is a recently-identified alternative receptor of SDF-1. Western blotting and flow cytometry assay results showed that considerable intracellular CXCR7 was expressed in EPC derived from human cord blood. We investigated the role of CXCR7 in EPC by blocking CXCR7 with antagonist CCX733. Multiple functional assays revealed that CXCR7 mediated human EPC survival exclusively, mediated tube formation and matrix metalloproteinase-2 (MMP-2) production along with CXCR4. Blocking CXCR7 with CCX733 impaired EPC adhesion to active HUVEC and trans-endothelial migration induced by SDF-1, but had no effect on EPC migration, proliferation or nitric oxide (NO) production. These results indicated that CXCR7 plays a critical role in EPC homing and participating in angiogenesis, and may be a potential target molecule in anti-angiogenesis therapy for RA.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords